Drugs / APG777
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07027527 | Jun 2025 → Aug 2026 overdue | atopic eczema | Apogee Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06920901 | Mar 2025 → Sep 2026 overdue | asthma | Apogee Therapeutics, Inc. | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07003425 | May 2025 → Dec 2029 expected | atopic eczema | Apogee Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06395948 | Apr 2024 → Nov 2026 expected | atopic eczema | Apogee Therapeutics, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-09-30 | Vitae Pharmaceuticals, Inc. | Results AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 abbvie.com ↗
Phase 2 data in adults with atopic dermatitis showed that all three zumilokibart dose regimens met the primary endpoint, with significantly greater improvements in Eczema Area and Severity Index -75 (EASI-75) response rates versus placebo at Week 16 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-09-30 | Vitae Pharmaceuticals, Inc. | AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026 abbvie.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APG777 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07027527 ↗ |
| Action | Inhibit | “Preclinical Safety of APG777, A Novel Extended Half-Life Anti-Interleukin-13 Monoclonal Antibody” PMID 40739793 ↗ Jul 2025 |
| Modality | Monoclonal antibody | “APG777 is a humanized IgG1 monoclonal antibody” PMID 40739793 ↗ Jul 2025 |
| Route | Subcutaneous | “APG777 subcutaneous injection” NCT06395948 ↗ |
| Target | IL13 | “APG777 has high affinity to IL-13” PMID 40739793 ↗ Jul 2025 |